Stimulation of Cardiac Apoptosis in Essential Hypertension
Why the study?
Does losartan reduce cardiac apoptosis compared to amlodipine in patients with essential hypertension?
Population
28 patients with essential hypertension and no evidence of either ischemic cardiomyopathy or heart failure.
Comparison
Losartan for 12 months vs Amlodipine for 12 months
Design
RCT, Randomized (method not specified)
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Losartan may confer BP-independent cardiac protection in hypertension; extends evidence for ARB-specific effects on remodeling beyond amlodipine.
Structured PICO
Does losartan reduce cardiac apoptosis compared to amlodipine in patients with essential hypertension?
P
Population
28 patients with essential hypertension and no evidence of either ischemic cardiomyopathy or heart failure.
I
Intervention
Losartan for 12 months
C
Comparator
Amlodipine for 12 months
O
Outcome
Number of apoptotic nuclei assessed by DNA end-labeling (TUNEL) and immunostaining for active caspase-3 from right septal endomyocardial biopsies at 12 monthssurrogate
Losartan, but not amlodipine, reduces cardiac apoptosis in essential hypertension independently of blood pressure lowering, highlighting a specific role for angiotensin II in hypertensive cardiac remodeling.
Cite This Study
González et al. (2002) studied this question.